Important Safety Information  |  
Search

PROSTATEinfo.com - Information on prostate cancer for patients and professionals
AstraZeneca
Click Here for Health Care Professional Site
  • Home
  • About Prostate Cancer
    • What is Cancer?
    • What is the Prostate?
    • What Should I Know About Prostate Cancer?
    • What are Risk Factors for Prostate Cancer?
  • The Diagnosis
    • Screening & Detection
    • Biopsy
    • Testing
    • Coping With Prostate Cancer
    • Questions to Ask Your Doctor
  • Grading & Staging
    • Gleason Grading System
    • Staging
  • Treatment Options
    • Treatment Options
    • Prostatectomy
    • Radiation Therapy
    • Cryotherapy
    • Watchful Waiting
    • Hormonal Therapy
    • Chemotherapy
    • Investigational Therapy
    • Other Treatment Info
  • After Treatment
    • After Treatment
    • Questions to Ask Your Doctor
  • About Clinical Research Trials
  • Support Resources
    • Support Groups & Resources
    • Patient Assistance
  • Printable Brochures
  • Glossary
Site Map

For Patients

Patients Home Page

About Prostate Cancer
What is Cancer?
What is the Prostate?
What Should I Know About Prostate Cancer?
What are Risk Factors for Prostate Cancer?

The Diagnosis
Screening & Detection
Biopsy
Testing
Coping With Prostate Cancer
Questions to Ask Your Doctor

Grading & Staging
Gleason Grading System
Staging

Treatment Options
Treatment Options
Prostatectomy
Radiation Therapy
Cryotherapy
Watchful Waiting
Hormonal Therapy
Chemotherapy
Investigational Therapy
Other Treatment Info

After Treatment
After Treatment
Questions to Ask Your Doctor

About Clinical Research Trials

Support Resources
Support Groups & Resources
Patient Assistance

Printable Brochures

Glossary

Prescribing Information

Send to a Friend

Prescribing Information
Print This Page
Send to a Friend
Change Text Size - A A A
Visit the support resources section! Resources for patients including support groups and printable brochures.
Site Map  |  Contact Us  |  Privacy Statement  |  Legal Information

Important Information About CASODEX (bicalutamide) Tablets

CASODEX at a dose of 50 mg daily is a prescription medication approved for use in combination with an injection of a luteinizing hormone-releasing hormone analog (LHRH-A) for treatment of advanced prostate cancer (metastatic Stage D2).

CASODEX at a dose of 150 mg daily is not approved for use alone or with other treatments. See full Prescribing Information under the section on "CLINICAL PHARMACOLOGY–Clinical Studies–Safety Data from Clinical Studies using CASODEX 150 mg" for additional important safety information regarding CASODEX 150 mg.

Important Safety Information About CASODEX

There have been reports of liver function problems during treatment with CASODEX. Therefore, your doctor will monitor your liver function with a blood test before you start treatment with CASODEX, at regular intervals during the first 4 months of treatment, and at regular times after that.

The most common side effects that occurred during treatment with CASODEX plus an injection of an LHRH-A were hot flashes (53%), pain (21% to 35%, including pelvic, back, and general), weakness (22%), and constipation (22%). Other side effects (reported in 12% to 18% of patients) were urination at night, blood in urine, diarrhea, swelling, shortness of breath, nausea, and infection.

Please click here for full Prescribing Information for CASODEX.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.


Important Information About ZOLADEX (goserelin acetate implant)

ZOLADEX is a prescription medication approved for use in combination with flutamide (an antiandrogen) plus radiotherapy for locally advanced prostate cancer. Treatment with the combination should start 8 weeks prior to starting and continue during radiation therapy.

ZOLADEX is also approved to use alone for patients with advanced prostate cancer. ZOLADEX may help reduce the size of your cancer and reduce your symptoms (palliative treatment).

Important Safety Information About ZOLADEX

ZOLADEX, like other luteinizing hormone-releasing hormone analogs (LHRH-As), may cause an initial rise in testosterone. When used alone, there may be a temporary worsening of prostate cancer symptoms at the start of therapy.

Common side effects that occurred during treatment with ZOLADEX plus flutamide and radiation therapy or ZOLADEX alone included hot flashes, decrease in sexual desire and/or ability to have erections, diarrhea, pain (general, pelvic, and bone), lower urinary tract symptoms, fatigue, nausea, breast growth, swelling, rash, upper respiratory infection, and sweating.

Please click here for full Prescribing Information for ZOLADEX 3.6 mg 1-month Depot.
Please click here for full Prescribing Information for ZOLADEX 10.8 mg 3-month Depot.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.


CASODEX and ZOLADEX are registered trademarks of the AstraZeneca group of companies.

This product information is intended for US audiences only. This information is intended for US consumers only.

©2008 AstraZeneca Pharmaceuticals LP. All rights reserved. 257989  6/08

US Corporate Site